A5020903295- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Lung Cancer Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- Medical Imaging and Pathology Studies
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- RNA modifications and cancer
- Colorectal Cancer Treatments and Studies
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer therapeutics and mechanisms
- Radiomics and Machine Learning in Medical Imaging
- Epigenetics and DNA Methylation
- MicroRNA in disease regulation
- Immunotherapy and Immune Responses
- HER2/EGFR in Cancer Research
- Pancreatic and Hepatic Oncology Research
- Immune Cell Function and Interaction
- Cancer Mechanisms and Therapy
- Neuroendocrine Tumor Research Advances
- Gastric Cancer Management and Outcomes
- Cancer-related gene regulation
- Quinazolinone synthesis and applications
- Neonatal Respiratory Health Research
- Pulmonary Hypertension Research and Treatments
Yonsei University
2016-2025
Severance Hospital
2016-2025
Brigham and Women's Hospital
2024
Massachusetts General Hospital
2015-2019
Yonsei University Health System
2013-2017
Sungkyunkwan University
2016-2017
Seoul National University
2017
Chungbuk National University
2017
Samsung (South Korea)
2016
Kyungpook National University Hospital
2014
Purpose ROS1 rearrangement is a distinct molecular subset of non–small-cell lung cancer (NSCLC). We investigated the efficacy and safety ceritinib in patients with ROS1-rearranged NSCLC. Patients Methods enrolled 32 advanced NSCLC who tested positive for by fluorescent situ hybridization. Ceritinib 750 mg was administered once daily. The primary end point objective response rate. secondary points were disease control rate; duration response; progression-free survival; overall toxicity;...
Purpose To investigate the frequency and prognostic role of fibroblast growth factor receptor 1 (FGFR1) amplification in patients with surgically resected squamous cell carcinoma lung (SCCL) association between smoking FGFR1 amplification. Patients Methods Gene copy number was investigated microarrayed tumors from 262 SCCL who had tumor tissue as well survival data available. evaluated by fluorescent situ hybridization, an FGFR1-amplified (FGFR1 amp + ) prespecified a nine or more copies...
Abstract BACKGROUND: The objectives of this study were to determine the proportions major oncogenic alterations and examine survival in genotype‐specific subsets never‐smokers with nonsmall cell lung cancer (NSCLC). METHODS: authors concurrently analyzed mutations epidermal growth factor receptor ( EGFR ) v‐Ki‐ ras 2 Kirsten rat sarcoma viral oncogene homolog KRAS genes investigated anaplastic lymphoma kinase ALK gene rearrangements samples from 229 NSCLC. identified by fluorescent situ...
Purpose We obtained intravoxel incoherent motion (IVIM) parameters through biexponential analysis on diffusion‐weighted MR imaging (DWI) using multiple b values. Correlation was evaluated between these and histological microvessel density (MVD) for the possibility of noninvasive evaluation MVD with DWI. Methods Twenty‐five nude mice HT29 colorectal cancer cells implanted were analyzed after undergoing DWI values (0, 50, 100, 300, 500, 700, 1000 s/mm 2 ). Tissue diffusivity ( D t ),...
Abstract Background. Non-small cell lung cancers (NSCLCs) harboring specific genetic alterations can be highly sensitive to targeted therapies. Materials and Methods. We performed a rearrangement assay on 54 NSCLCs across all stages that were from patients who never smokers did not have driver mutations. Because MET exon 14 skipping was the most frequent alteration found, we surveyed results for at Massachusetts General Hospital (MGH) since inclusion of this into our current molecular...
Human epidermal growth factor receptor 2 (HER2 or ErbB2) can be overexpressed, amplified and/or mutated in malignant tumors, and is a candidate for therapeutic targeting. However, molecular associations clinical significances of these alterations were controversial lung cancer. In this study, we investigated the frequency clinicopathological significance HER2 dysregulation patients with adenocarcinoma. protein overexpression, gene amplification, mutation evaluated by immunohistochemistry...
Although first-line crizotinib treatment leads to clinical benefit in ROS1+ lung cancer, high prevalence of crizotinib-resistant ROS1-G2032R (ROS1G2032R) mutation and progression the central nervous system (CNS) represents a therapeutic challenge. Here, we investigated antitumor activity repotrectinib, novel next-generation ROS1/TRK/ALK-tyrosine kinase inhibitor (TKI) patient-derived preclinical models.Antitumor repotrectinib was evaluated models including treatment-naïve ROS1G2032R further...
<h3>Background</h3> Regulatory T (T<sub>reg</sub>) cells have an immunosuppressive function in cancer, but the underlying mechanism of immunosuppression tumor microenvironment (TME) is unclear. <h3>Methods</h3> We compared phenotypes cell subsets, including T<sub>reg</sub> cells, obtained from peripheral blood, malignant effusion, and tumors 103 cancer patients. Our primary focus was on expression immune checkpoint (IC)-molecules, such as programmed death (PD)-1, T-cell immunoglobulin...
Immune checkpoint inhibitors (ICI) have shown marked responses in patients with non-small cell lung cancer (NSCLC) clinical trials. However, because such trials comprise cohorts selected based on specific criteria, it is unclear if their results represent routine practice.We examined 155 advanced NSCLC who were administered either nivolumab or pembrolizumab at Yonsei Cancer Center, Korea between March 2014 and January 2019. Patient characteristics, EGFR/ALK mutation status, metastatic...
Context.—The proposed International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification lung adenocarcinomas has been published. Objective.—To evaluate correlation between epidermal growth factor receptor mutations and histologic subtypes according to upcoming new adenocarcinomas. Design.—Medical records pathologic slides were reviewed a total 107 surgically resected All tumors reclassified predominant subtype, comprehensive...
ROS1 rearrangement is a predictive biomarker for response to the tyrosine kinase inhibitor, crizotinib. We investigated usefulness of immunohistochemistry (IHC) detection patients who harbor rearrangements in two separate cohorts. also compared IHC with ALK terms diagnostic performance predict each gene rearrangement. In retrospective cohort, was performed 219 cases lung adenocarcinoma already known genetic alterations. prospective we 111 consecutive and confirmed results by subsequent FISH....
The development of chemo-resistance in non-small lung cancer is a major obstacle treating patients. Hypoxia commonly faced microenvironment solid tumor and suggested to be related both autophagy chemo-resistance. In this study, we investigated the role hypoxia-induced acquiring cell (A549) human tissue Hypoxic exposure (1 % O2) A549 stimulated autophagic induction cells, shown by increase LC3BI LC3BII conversion decrease p62/sequestosome1 Western blot, increased GFP-LC puncta confocal...
EGFR mutation-induced cell proliferation causes changes in tumor biology and metabolism, which may reflect marker concentration 18F-FDG uptake on PET/CT. Direct aspirates of primary lung tumors contain different concentrations markers than serum markers, correlate better with mutation markers. The purpose this study is to investigate an association between cytologic FDG status non-small cancer (NSCLC). We prospectively collected 61 patients who underwent analysis. Serum CYFRA 21-1, CEA, SCCA...